Finance

Lists
Why is ZBIO up ၂.၁၇%?
Dive Deeper
ZBIO:NASDAQ
Zenas Biopharma Inc
၂၅.၄၀ US$
+၂.၁၇%
(+၀.၅၄) 1D
၂၅.၄၀ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၁၅, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
၂၄.၉၆ US$
High
၂၅.၉၄ US$
Low
၂၄.၂၅ US$
Mkt. cap
၁၆၅.၅၅ ဋေ
Avg. vol.
၆.၈၂ သိန်း
Volume
၀.၀၀
52-wk high
၄၄.၅၄ US$
52-wk low
၁၃.၅၀ US$
EPS
-၈.၉၇ US$
Shares outstanding
၆.၅၂ ကုဋေ
No. of employees
၁၆၇
Open
၂၄.၉၆ US$
High
၂၅.၉၄ US$
Low
၂၄.၂၅ US$
Mkt. cap
၁၆၅.၅၅ ဋေ
Avg. vol.
၆.၈၂ သိန်း
Volume
၀.၀၀
52-wk high
၄၄.၅၄ US$
52-wk low
၁၃.၅၀ US$
EPS
-၈.၉၇ US$
Shares outstanding
၆.၅၂ ကုဋေ
No. of employees
၁၆၇
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၂၂ မိနစ်
Zenas BioPharma (ZBIO) INDIGO Data Puts Its Bull Case Back In Focus
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၂ ရက်
H.C. Wainwright reiterates Zenas Biopharma stock rating at buy
TipRanks
TipRanks
·
ပြီးခဲ့သည့် ၂ ရက်
Zenas BioPharma Highlights New Phase 3 Obexelimab Data
About Zenas Biopharma Inc
CEO-
Employees၁၆၇
Founded၂၀၁၉
HeadquartersWaltham, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current ၂၅.၄၀ US$
၅၅.၀၀ US$ (+၁၁၆.၅၄%)
Average
၄၄.၈၀ US$ (+၇၆.၃၈%)
Lowest
၃၂.၀၀ US$ (+၂၅.၉၈%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Buy
Maintained
၄၅.၀၀ US$
+၇၇.၂%
10/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
၄၄.၀၀ US$
+၇၃.၂%
10/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
၄၈.၀၀ US$
+၈၉%
10/12/2026
Martin Fan
Wedbush
Buy
Maintained
၄၅.၀၀ US$
+၇၇.၂%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
၃၂.၀၀ US$
+၂၆%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
၄၅.၀၀ US$
+၇၇.၂%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
၅၅.၀၀ US$
+၁၁၆.၅%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
၄၄.၀၀ US$
+၇၃.၂%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
၅၅.၀၀ US$
+၁၁၆.၅%
03/17/2026
Last report
၂၀၂၆ ဩ ၁၃
Fiscal period
Q2 2026
-၁.၇၇ US$ / -၀.၇၅ US$
-၁၃၄.၄၄%miss
Revenue / Est. (USD)
၁.၀၀ သန်း / ၁.၅၀ ကုဋေ
-၉၃.၃၃%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
၁.၀၀ သန်း
Cost of goods sold
၃.၄၄ ကုဋေ
၅.၅၇ ကုဋေ
၆.၀၄ ကုဋေ
၆.၂၉ ကုဋေ
Cost of revenue
၃.၄၄ ကုဋေ
၅.၅၇ ကုဋေ
၆.၀၄ ကုဋေ
၆.၂၉ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၃၂ ကုဋေ
၁.၅၆ ကုဋေ
၁.၆၉ ကုဋေ
၁.၅၇ ကုဋေ
Operating expense
၁.၃၂ ကုဋေ
၁.၅၆ ကုဋေ
၁.၆၉ ကုဋေ
၁.၅၇ ကုဋေ
Total operating expenses
၄.၇၆ ကုဋေ
၇.၁၃ ကုဋေ
၇.၇၄ ကုဋေ
၇.၈၇ ကုဋေ
Operating income
-၄.၇၆ ကုဋေ
-၇.၁၃ ကုဋေ
-၇.၇၄ ကုဋေ
-၇.၇၇ ကုဋေ
Other non operating income
၁.၀၈ သန်း
-၇.၄၈ သန်း
-၂.၄၀ သောင်း
၁.၆၀ သောင်း
EBT including unusual items
-၅.၁၅ ကုဋေ
-၂၄.၀၃ ကုဋေ
-၈.၁၀ ကုဋေ
-၁၁.၁၃ ကုဋေ
EBT excluding unusual items
-၄.၆၅ ကုဋေ
-၇.၃၇ ကုဋေ
-၈.၁၀ ကုဋေ
-၈.၁၃ ကုဋေ
Income tax expense
-
၁.၀၆ သိန်း
-
၁.၁၄ သိန်း
Effective tax rate
-
-၀.၀၄%
-
-၀.၁၀%
Other operating expenses
-
-
-
-
Net income
-၅.၁၅ ကုဋေ
-၂၄.၀၄ ကုဋေ
-၈.၁၀ ကုဋေ
-၁၁.၁၅ ကုဋေ
Net profit margin
-
-
-
-၁၁,၁၄၅.၆၀%
Earnings per share
-၁.၂၂
-၁.၃၉
-၁.၄၆
-၁.၇၇
Interest and investment income
-
၁.၂၂ ကုဋေ
၃.၀၂ သန်း
၆.၆၀ သန်း
Interest expense
-
-၇.၃၃ သန်း
-၆.၆၃ သန်း
-၁.၀၃ ကုဋေ
Net interest expenses
-
၄.၈၂ သန်း
-၃.၆၁ သန်း
-၃.၇၀ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၇၆ ကုဋေ
-၇.၁၃ ကုဋေ
-၇.၇၃ ကုဋေ
-၇.၇၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ